Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
Abstract Background Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) repre...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Cell Communication and Signaling |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12964-025-02056-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585487556018176 |
|---|---|
| author | Yinan Xiao Yu Wu Qilong Wang Mo Li Chaolin Deng Xiaoyang Gu |
| author_facet | Yinan Xiao Yu Wu Qilong Wang Mo Li Chaolin Deng Xiaoyang Gu |
| author_sort | Yinan Xiao |
| collection | DOAJ |
| description | Abstract Background Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) represents a major challenge for the clinical management of HGSOC, highlighting the necessity for the development of novel therapeutic strategies. This study investigated the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a pivotal regulator of glycolysis, in PARPi resistance and explored its potential as a therapeutic target to overcome PARPi resistance. Methods We conducted in vitro and in vivo experiments to assess the role of PFKFB3 in OC and its impact on PARPi resistance. We analyzed PFKFB3 expression and activity in primary OC tissues and cell lines using western blotting and immunohistochemistry. CRISPR-Cas9 and pharmacological inhibitors were employed to inhibit PFKFB3, and the effects on PARPi resistance, homologous recombination (HR) repair efficiency, and DNA damage were evaluated. RNA sequencing and proximity labeling were employed to identify the molecular mechanisms underlying PFKFB3-mediated resistance. The in vivo efficacy of PARPi and PFK158 combination therapy was evaluated in OC xenograft models. Results PFKFB3 activity was significantly elevated in OC tissues and associated with PARPi resistance. Inhibition of PFKFB3, both genetically and pharmacologically, sensitized OC cells to PARPis, impaired HR repair and increased DNA damage. Proximity labeling revealed replication protein A3 (RPA3) as a novel PFKFB3-binding protein involved in HR repair. In vivo, the combination of PFK158 and olaparib significantly inhibited tumor growth, increased DNA damage, and induced apoptosis in OC xenografts without exacerbating adverse effects. Conclusions Our findings demonstrate that PFKFB3 is crucial for PARPi resistance in OC. Inhibiting PFKFB3 sensitizes HR-proficient OC cells to PARPis by impairing HR repair, leading to increased DNA damage and apoptosis. PFKFB3 represents a promising therapeutic target for overcoming PARPi resistance and improving outcomes in OC patients. |
| format | Article |
| id | doaj-art-43604a8132934cd1a0ef6f1a8d0eaf66 |
| institution | Kabale University |
| issn | 1478-811X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Communication and Signaling |
| spelling | doaj-art-43604a8132934cd1a0ef6f1a8d0eaf662025-01-26T12:44:45ZengBMCCell Communication and Signaling1478-811X2025-01-0123112110.1186/s12964-025-02056-8Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repairYinan Xiao0Yu Wu1Qilong Wang2Mo Li3Chaolin Deng4Xiaoyang Gu5Department of Obstetrics and Gynecology, Peking University Third HospitalDepartment of Obstetrics and Gynecology, Peking University Third HospitalCenter of Medical and Health Analysis, Peking University Health Science CenterDepartment of Obstetrics and Gynecology, Peking University Third HospitalDepartment of Hepatobiliary Surgery, Peking University People’s HospitalDepartment of Obstetrics and Gynecology, Peking University Third HospitalAbstract Background Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) represents a major challenge for the clinical management of HGSOC, highlighting the necessity for the development of novel therapeutic strategies. This study investigated the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a pivotal regulator of glycolysis, in PARPi resistance and explored its potential as a therapeutic target to overcome PARPi resistance. Methods We conducted in vitro and in vivo experiments to assess the role of PFKFB3 in OC and its impact on PARPi resistance. We analyzed PFKFB3 expression and activity in primary OC tissues and cell lines using western blotting and immunohistochemistry. CRISPR-Cas9 and pharmacological inhibitors were employed to inhibit PFKFB3, and the effects on PARPi resistance, homologous recombination (HR) repair efficiency, and DNA damage were evaluated. RNA sequencing and proximity labeling were employed to identify the molecular mechanisms underlying PFKFB3-mediated resistance. The in vivo efficacy of PARPi and PFK158 combination therapy was evaluated in OC xenograft models. Results PFKFB3 activity was significantly elevated in OC tissues and associated with PARPi resistance. Inhibition of PFKFB3, both genetically and pharmacologically, sensitized OC cells to PARPis, impaired HR repair and increased DNA damage. Proximity labeling revealed replication protein A3 (RPA3) as a novel PFKFB3-binding protein involved in HR repair. In vivo, the combination of PFK158 and olaparib significantly inhibited tumor growth, increased DNA damage, and induced apoptosis in OC xenografts without exacerbating adverse effects. Conclusions Our findings demonstrate that PFKFB3 is crucial for PARPi resistance in OC. Inhibiting PFKFB3 sensitizes HR-proficient OC cells to PARPis by impairing HR repair, leading to increased DNA damage and apoptosis. PFKFB3 represents a promising therapeutic target for overcoming PARPi resistance and improving outcomes in OC patients.https://doi.org/10.1186/s12964-025-02056-8Ovarian cancerPFKFB3PARP inhibitorsHomologous recombination repair |
| spellingShingle | Yinan Xiao Yu Wu Qilong Wang Mo Li Chaolin Deng Xiaoyang Gu Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair Cell Communication and Signaling Ovarian cancer PFKFB3 PARP inhibitors Homologous recombination repair |
| title | Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair |
| title_full | Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair |
| title_fullStr | Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair |
| title_full_unstemmed | Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair |
| title_short | Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair |
| title_sort | repression of pfkfb3 sensitizes ovarian cancer to parp inhibitors by impairing homologous recombination repair |
| topic | Ovarian cancer PFKFB3 PARP inhibitors Homologous recombination repair |
| url | https://doi.org/10.1186/s12964-025-02056-8 |
| work_keys_str_mv | AT yinanxiao repressionofpfkfb3sensitizesovariancancertoparpinhibitorsbyimpairinghomologousrecombinationrepair AT yuwu repressionofpfkfb3sensitizesovariancancertoparpinhibitorsbyimpairinghomologousrecombinationrepair AT qilongwang repressionofpfkfb3sensitizesovariancancertoparpinhibitorsbyimpairinghomologousrecombinationrepair AT moli repressionofpfkfb3sensitizesovariancancertoparpinhibitorsbyimpairinghomologousrecombinationrepair AT chaolindeng repressionofpfkfb3sensitizesovariancancertoparpinhibitorsbyimpairinghomologousrecombinationrepair AT xiaoyanggu repressionofpfkfb3sensitizesovariancancertoparpinhibitorsbyimpairinghomologousrecombinationrepair |